AVITA Medical, Inc. (RCEL): Price and Financial Metrics
GET POWR RATINGS... FREE!
RCEL Stock Price Chart Interactive Chart >
RCEL Price/Volume Stats
|Current price||$20.64||52-week high||$32.10|
|Prev. close||$20.59||52-week low||$16.87|
|Day high||$21.11||Avg. volume||156,123|
|50-day MA||$19.36||Dividend yield||N/A|
|200-day MA||$22.12||Market Cap||512.76M|
AVITA Medical, Inc. (RCEL) Company Bio
AVITA Medical, Inc. operates as a medicine company. The Company focuses on the development and commercialization of therapies to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. AVITA Medical serves customers worldwide.
RCEL Latest News Stream
|Loading, please wait...|
RCEL Latest Social Stream
View Full RCEL Social Stream
Latest RCEL News From Around the Web
Below are the latest news stories about AVITA Medical Inc that investors may wish to consider to help them evaluate RCEL as an investment opportunity.
AVITA Medical (RCEL) announces preliminary financial results for fiscal Q4 2021. For Q4 ending June 30, 2021, the company is raising its guidance to be in range of $9.5M to $9.7M (consensus $7.06M), consisting of $6.0M to $6.2M of RECELL commercial revenue and $3.5M of RECELL revenue associated with BARDA.The company's previously...
VALENCIA, Calif. and MELBOURNE, Australia, June 15, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021. For the fiscal quarter ending June 30, 2021, AVITA Medical has to date realized total revenue in excess of its
FDA gives green light to Avita''s ''spray-on'' burns treatment for children, shares gain - Stockhead
Burns treatment company Avita Medical (ASX:AVH) won further approval from the FDA to treat a wider variety of burns and in paediatric patients too.
In a report released today, Ryan Zimmerman from BTIG reiterated a Buy rating on Avita Medical (RCEL), with a price target of $37.00. The post BTIG Thinks Avita Medicals Stock is Going to Recover appeared first on Smarter Analyst .
The AVITA Medical Inc (ASX:AVH) share price is up more than 14% after getting some positive news from the US FDA. The information in this article contains general financial advice only and is authorised by The Rask Group Pty Ltd (ABN: 36 622 810 995). That means, the advice does not take into account your objectives, financial situation or needs. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you do not know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. Please take a moment to read our Financial Services Guide (FSG) . The post Why the AVITA (ASX:AVH) share price is booming appeared first on Rask Media .
RCEL Price Returns